Miss Maryam Latarani

EZH2 inhibition enhances the activity of Carboplatin in aggressive-variant prostate cancer cell lines (2025)
Latarani, Maryam; Pucci, Perla; Eccleston, Mark; Manzo, Massimiliano; Gangadharannambiar, Priyadarsini; Fischetti, Irene; Alborelli, Ilaria; Mongiardini, Vera; Mahmood, Namra; Colombo, Mario Paolo; Grimaldi, Benedetto; Rigas, Sushila; Akamatsu, Shusuke; Hawkes, Cheryl; Wang, Yuzhuo; Jachetti, Elena and Crea, Francesco
Epigenomics, 17(3) (pp. 145-154)

Predictive significance of circulating histones in hepatocellular carcinoma patients treated with sorafenib (2022-05)
Salani, Francesca; Latarani, Maryam; Casadei-Gardini, Andrea; Gangadharannambiar, Priyadarsini; Fornaro, Lorenzo; Vivaldi, Caterina; Pecora, Irene; Massa, Valentina; Marisi, Giorgia; Canale, Matteo; Ulivi, Paola; Scartozzi, Mario; Eccleston, Mark; Masi, Gianluca and Crea, Francesco
Epigenomics, 14(9) (pp. 507-517)

EZH2 inhibition: a promising strategy to prevent cancer immune editing (2020-08)
Kang, Ning; Eccleston, Mark; Clermont, Pier-Luc; Latarani, Maryam; Male, David Kingsley; Wang, Yuzhuo and Crea, Francesco
Epigenomics, 12(16)

EZH2 as a therapeutic target for aggressive prostate cancer (2020-10-05)
Latarani, Maryam; Pucci, Perla; Roig-Carles, David; Eccleston, Mark; Xue, Hui; Hawkes, Cheryl; Rigas, Sushila; Wang, Yuzhuo and Crea, Francesco
In : Crick Cancer Research Symposium, iPoster (5-6 Oct 2020, The Francis Crick Institute and Virtual)

EZH2 as a therapeutic target for aggressive prostate cancer (2023-01-11)
Latarani, Maryam
mphil thesis The Open University